Emtricitabine and tenofovir alafenamide

(Descovy®)

Emtricitabine and tenofovir alafenamide

Drug updated on 1/24/2024

Dosage FormTablet (oral; emtricitabine/tenofovir alafenamide; 200 mg/25 mg
Drug ClassNucleoside reverse transcriptase inhibitors (NRTIs)
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.
  • Indicated in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor for the treatment of HIV-1 infection in pediatric patients weighing at least 14 kg and less than 35 kg.
  • Indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sexual acquisition, excluding individuals at risk from receptive vaginal sex. Individuals must have a negative HIV-1 test immediately prior to initiating DESCOVY for HIV-1 PrEP.

Product Monograph / Prescribing Information

Document TitleYearSource
Descovy (emtricitabine and tenofovir alafenamide) Prescribing Information.2022Gilead Sciences, Inc., Foster City, CA

Randomized Controlled Trials

Clinical Practice Guidelines